BrightGene’s Phase III Obesity Drug Data Signals Shift From Weight Loss to Full Cardiometabolic Care

BrightGene Bio-Medical Technology Co., Ltd. has reported positive topline Phase III results for BGM0504, its investigational GLP-1/GIP dual receptor agonist for overweight and obesity.

While the obesity drug market has largely focused on maximizing weight reduction percentages, BrightGene is positioning BGM0504 differently — as a broader cardiometabolic therapy capable of simultaneously improving blood pressure, lipid metabolism, uric acid, glucose control, and bone health alongside weight loss.

The company’s latest data suggests the obesity treatment landscape may be entering a new phase where success is no longer measured by weight loss alone.

BGM0504 Achieved 19.3% Mean Weight Loss

In the Phase III trial, participants receiving BGM0504 achieved:

• Mean weight reduction of 19.3%
• Waist circumference reduction of 16.5 cm
• Strong improvements across multiple metabolic markers

The results place BGM0504 near the upper range of efficacy currently seen among global GLP-1/GIP dual agonists. Notably, the company emphasized that efficacy was observed even at lower doses, with progressively greater weight reduction at higher doses while maintaining relatively stable tolerability.

Deep Weight Loss Outcomes

The study also showed strong outcomes in clinically meaningful deep weight loss categories.

In the 15 mg treatment group:

• 67.3% of participants achieved ≥15% weight loss
• 48.9% achieved ≥20% weight loss

Nearly half of patients entering the ≥20% weight loss category places the therapy closer to the range historically associated with bariatric interventions.

Waist Circumference Reduction Highlights Visceral Fat Impact

BrightGene repeatedly emphasized waist circumference reduction as a major differentiator. The reported 16.5 cm reduction suggests substantial decreases in visceral fat, which is closely associated with:

• Cardiovascular disease risk
• Insulin resistance
• Hypertension
• Type 2 diabetes

As obesity drug development matures, waist circumference and fat distribution are increasingly viewed as more clinically relevant than body weight alone.

The company argues that BGM0504’s benefits extend beyond cosmetic weight reduction toward meaningful metabolic risk improvement.

Blood Pressure Results May Be One of the Most Important Findings

Perhaps the most striking aspect of the dataset was the magnitude of blood pressure improvement.

Among participants with obesity and uncontrolled hypertension:

• Systolic blood pressure decreased by 22.9 mmHg
• Diastolic blood pressure decreased by 12.9 mmHg
• 92.9% of patients achieved blood pressure targets

These reductions are comparable to outcomes often seen with multi-drug antihypertensive therapy.

Why This Matters?

Obesity, hypertension, and diabetes frequently occur together clinically and collectively drive cardiovascular risk. Traditional antihypertensive monotherapy often reduces systolic blood pressure by approximately 8–12 mmHg.

According to BrightGene, the blood pressure reductions observed with BGM0504 approached the upper range typically seen with dual or triple combination antihypertensive therapy.

Importantly, the company noted:

• No hypotensive events were observed
• Blood pressure improvements appeared metabolically driven rather than caused by direct antihypertensive mechanisms

This may support the idea that treating obesity-related metabolic dysfunction can indirectly improve cardiovascular risk factors at scale.

Uric Acid Reduction Suggests Potential Gout Benefits

The trial also demonstrated significant improvements in uric acid levels. Participants experienced:

• Mean uric acid reduction of 70.7 μmol/L

BrightGene noted that this magnitude approaches the intervention range of standard uric acid-lowering therapies commonly used in gout management.

Because hyperuricemia and obesity frequently coexist, the findings may expand interest in obesity therapies that also reduce gout risk.

Lipid Improvements Add to the Cardiometabolic Profile

The company also reported broad improvements in lipid metabolism. Compared with previously reported data for tirzepatide, BrightGene claimed stronger reductions in several lipid parameters, including:

• Triglycerides: approximately 33.6% reduction
• LDL cholesterol: approximately 12.7% reduction
• Total cholesterol: approximately 7.4% reduction

The company suggested these changes indicate overall improvement in cardiovascular risk profiles rather than isolated metabolic effects.

Bone Mineral Density Findings Could Differentiate BGM0504

One particularly notable finding involved bone health. Weight loss therapies have sometimes raised concerns regarding reductions in bone mineral density (BMD), partly due to decreased skeletal loading during rapid weight loss.

However, after 52 weeks of treatment, participants receiving BGM0504 demonstrated increases in:

• Total body BMD: +0.3%
• Lumbar spine BMD: +1.4%
• Hip BMD: +3.9%

If confirmed in further studies, this could become a meaningful differentiator in long-term obesity management.

Safety and Tolerability Stand Out

Safety remains one of the most important factors for long-term obesity treatment adherence. BrightGene reported exceptionally low discontinuation rates due to adverse events:

• High-dose group discontinuation rate: only 0.7%

Interestingly, discontinuation rates did not increase with dose escalation, which differs from trends commonly observed with competing GLP-1 therapies. The company highlighted this as evidence of:

• Stable tolerability
• Broad patient usability
• Consistent efficacy across populations

The Industry Is Moving Beyond Weight Loss Alone

The obesity drug market is rapidly evolving. Initially, competition centered primarily around:

• Total percentage weight loss
• Speed of weight reduction

Now, attention is increasingly shifting toward:

• Cardiovascular outcomes
• Metabolic risk reduction
• Long-term adherence
• Population-wide applicability
• Real-world chronic disease management

BrightGene is clearly positioning BGM0504 within this newer “cardiometabolic” framework.

Why Cardiometabolic Therapies Matter?

Cardiometabolic diseases encompass interconnected disorders such as:

• Obesity
• Type 2 diabetes
• Hypertension
• Dyslipidemia
• Heart disease
• Heart failure

These conditions rarely occur independently. Modern treatment strategies are increasingly focused on therapies capable of simultaneously improving multiple risk factors through a single intervention pathway.

BGM0504’s broad metabolic profile suggests its potential value may extend beyond standalone obesity treatment into multidimensional chronic disease management.

Final Thoughts

BrightGene’s Phase III data positions BGM0504 as more than another GLP-1/GIP weight loss drug.

While its 19.3% mean weight reduction is highly competitive, the broader cardiometabolic improvements may ultimately become the therapy’s most important differentiator.

If future studies confirm these findings, the obesity treatment market may continue evolving from a “weight loss race” into a broader effort to reshape long-term cardiometabolic health outcomes.